Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
28.46
+0.05 (0.18%)
At close: Dec 5, 2025, 4:00 PM EST
28.50
+0.04 (0.14%)
After-hours: Dec 5, 2025, 7:58 PM EST
Teva Pharmaceutical Revenue
Teva Pharmaceutical had revenue of $4.48B in the quarter ending September 30, 2025, with 3.42% growth. This brings the company's revenue in the last twelve months to $16.78B, up 0.02% year-over-year. In the year 2024, Teva Pharmaceutical had annual revenue of $16.54B with 4.40% growth.
Revenue (ttm)
$16.78B
Revenue Growth
+0.02%
P/S Ratio
1.94
Revenue / Employee
$455,498
Employees
36,830
Market Cap
32.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
| Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
| Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
| Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
| Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
TEVA News
- 1 day ago - Teva Pharmaceutical Industries Limited (TEVA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 6 days ago - 30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks - The Motley Fool
- 11 days ago - Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva® - GlobeNewsWire
- 14 days ago - Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi's 2025 Global Healthcare Conference in December - GlobeNewsWire
- 17 days ago - Teva seeks startups to help solve global pharmaceutical challenges - Reuters
- 18 days ago - Teva Pharmaceutical Industries Limited (TEVA) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 21 days ago - Generics Stalwart Teva Has Turned A Corner In Its Specialty Medicines Business - Seeking Alpha
- 25 days ago - Billionaire Stanley Druckenmiller Sold His Fund's Entire Stakes in Nvidia and Palantir for a Scorching-Hot Drug Stock That's Up 218% Since Mid-2023 - The Motley Fool